Biofrontera Inc. (BFRI)
NASDAQ: BFRIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BFRI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $9.51M
- Forward P/E
- 1.32
- EPS (TTM)
- -$0.26
- Dividend yield
- None
- 52-week range
- 0.53 – 1.66
- Day range
- 0.53 – 0.5882
- Volume / Avg
- 195.91K / 429.04K
- Beta
- —
- Shares outstanding
- 17.95M
52-week range
BFRI stock today
Shares of Biofrontera (BFRI) finished lower on Nov 20 at $0.53, a drop of 7.02% or $0.04 per share, versus the S&P 500's 3.70% decline. Trading was light, with 195.91K shares changing hands, about 46% of the average daily volume. Shares are 68.1% below their 52-week high of $1.66, set on Sep 8, 2026 and 0.0% above the 52-week low of $0.53, near the bottom of the past year's range.
BFRI is down 7.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 28.4%. Biofrontera has posted a net loss over the last twelve months (EPS of -$0.26), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Biofrontera
Company profileBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Hermann Luebbert Ph.D.
- Headquarters
- Woburn, MA
- Employees
- 84
- IPO year
- 2021
- Website
- biofrontera-us.com
Financial highlights
Full financialsIn fiscal 2025, Biofrontera generated $41.7 million in revenue, up 11.7% from fiscal 2024, its 5th consecutive year of revenue growth. Biofrontera reported a net loss of $10.5 million, compared with a loss of $17.8 million a year earlier. Operating margin was -27.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $41.70M | $37.32M | $34.07M | $28.67M | $24.10M |
| Growth | +11.75% | +9.54% | +18.82% | +18.98% | +27.86% |
| Net income | $-10.54M | $-17.76M | $-20.13M | $-640.00K | $-37.71M |
| EPS (diluted) | $-1.04 | $-3.22 | $-13.02 | $-0.61 | $-4.28 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$6.00+1032.08%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.59 vs —
BFRI news
All BFRI news- Biofrontera: 3 Key Takeaways for Long-Term InvestorsNasdaqBFRI, CFR
- Biofrontera Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue GrowthGlobeNewswire
- Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026GlobeNewswire
- Biofrontera Submits Ameluz SNDA For Expanded Actinic Keratosis UseNasdaq
- Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full BodyGlobeNewswire
- Biotech Stocks Facing FDA Decision In September 2026NasdaqBFRI, BMY, IONS, MIRM
Biofrontera peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CMMBChemomab Therapeutics Ltd. ADR | 1.19 | +4.39% | $9.58M | vs BFRI |
| RADXRadiopharm Theranostics Limited ADR | 0.6304 | -9.71% | $9.90M | vs BFRI |
| ASBPAspire-Lakewood Holdings Inc. | 7.13 | -5.44% | $10.00M | vs BFRI |
| GDTCCytoMed Therapeutics Limited | 0.755 | -2.33% | $9.01M | vs BFRI |
| CALCCalciMedica Inc. | 1.26 | +7.69% | $8.69M | vs BFRI |
| AEONAEON Biopharma Inc. Class A | 0.123 | -7.59% | $10.35M | vs BFRI |
| OPTHOptimi Health Corp. | 1.51 | -13.71% | $8.65M | vs BFRI |
| BIVIBioVie Inc. Class A | 0.80 | -12.07% | $8.58M | vs BFRI |
Indexes, lists and sector
Biofrontera stock FAQ
What is Biofrontera's stock price today?
BFRI last traded at $0.53 as of Nov 20, 4:00 PM EST, down 7.02% on the day. Prices are delayed at least 15 minutes.
Does Biofrontera pay a dividend?
No. Biofrontera does not currently pay a regular cash dividend.
Who is Biofrontera's CEO?
Dr. Hermann Luebbert Ph.D. is the chief executive officer of Biofrontera Inc., which has about 84 employees.
Has BFRI ever split its stock?
Yes. The most recent BFRI stock split was a 1-for-20 split on Jul 5, 2023.
What is the BFRI 52-week high?
The 52-week high for BFRI is $1.66 and the 52-week low is $0.53. The stock is currently 68.1% below its high.